Synopsys

SNPS earns a BUY rating with a $552.60 price target as 42% revenue growth trades at just 27x forward earnings, a clear market mispricing. CDNS trades at 43x forward earnings despite growing at half SNPS's pace, while ADSK commands 21x on just 16% revenue growth.

Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, today announced an expanded collaboration with Synopsys, Inc. — the leader in engineering solutions from silicon to systems — to advance gallium nitride (GaN) device modeling for radio frequency (RF) and power semiconductor applications. The work builds on the companies’ long-standing relationship around Synopsys’ Sentaurus™ TCAD and Atomera’s MSTcad™ toolset and extends the collaboration into GaN workflows to support bringing higher-quality GaN solutions to market.■

Synopsys delivered an outstanding third quarter with revenue, non-GAAP operating margin, and EPS all exceeding the high end of guidance. The company is experiencing increased demand for electronic design automation and intellectual property solutions, driven by the complexity of artificial intelligence compute and multidie architectures. Management raised full-year guidance for revenue, operating margin, and earnings per share, reflecting confidence in double-digit growth for the design automation segment. The company launched Multiphysics Fusion, representing the first joint solution integrating thermal analysis directly into the chip design flow. President and CEO Sassine Ghazi stated, "Multiphysics Fusion combines Synopsys and Ansys technology in the industry's only solution with thermal analysis fully integrated into the chip design flow." Management reported progress in agentic artificial intelligence, showcasing autonomous workflows that can reduce debug cycle time by up to 40% and accelerate design verification by up to 50-fold. The transition to the Factory 2 customized intellectual property model allows the company to move from a licensing-only structure to one that includes royalties. Sassine Ghazi noted, "It moves us up the value chain from licensing alone to licensing plus royalties and positions us to capture the fast-growing custom silicon opportunity."

Analyst(s): Futurum Research Publication Date: August 31, 2026 Synopsys Q3 FY 2026 earnings showed broad business strength, with EDA leading growth and Ansys adding momentum after the acquisition closed. The quarter also signaled a sharper focus on AI monetization, autonomous engineering workflows, and Design IP resource allocation heading into FY 2027.

Welcome to the Ansys SaberRD tutorial video series, a collection of short videos offering technical training, tips, and tricks for Saber software users. For more information on SaberRD software, please contact the Saber team. Video 1: Time Domain Analysis This video shows how to use Saber software’s built-in optimizer to optimize a design.

Highlights Strong quarterly performance reinforces Synopsys position in semiconductor software. AI-driven EDA demand is adding momentum to the companys growth story. Valuation and Ansys integration remain important areas of market scrutiny. Synopsys is gaining attention as AI demand and semiconductor complexity strengthen EDA opportunities, while Ansys integration, valuation expectations, competition, and execution remain key considerations.

Synopsys delivered an outstanding third quarter with revenue, non-GAAP operating margin, and EPS all exceeding the high end of guidance. The company raised its full-year revenue, non-GAAP operating margin, and EPS guidance due to strong operational execution and efficiency gains. The Design Automation segment achieved healthy growth in Q3, driven by strength in EDA, and is expected to accelerate to double-digit growth in Q4 and for the full year. The company launched Multiphysics Fusion, a joint solution with Ansys, and is seeing strong customer interest in its agentic AI platform. Synopsys is confident in its strategy and expects to capture a greater share of R&D investment across industries.

Gargi Ray, VP Finance, Synopsys Inc . Enterprise spending on artificial intelligence is soaring , yet many CFOs find themselves trapped in an uncomfortable paradox: massive capital allocation paired with small financial returns. According to research by Boston Consulting Group (BCG) in their report “ How to Get ROI from AI in the Finance Function ,” the median reported ROI for AI in finance sits at a meager 10%—far below the 20%-plus target many executives set.

India has built a strong semiconductor design ecosystem, but turning chip ideas into successful products requires much more than engineering. In an interview, Sudeep Shivalli of Synopsys India spoke to Nidhi Agarwal from Electronics For You about the challenges and opportunities shaping India’s chip industry.

The Health Savings Account (HSA) Premium Plan is effective 01-01-2026 and provides coverage under a high-deductible health plan compatible with HSAs. The Claims Administrator allows members to designate a Primary Care Physician from its network and ensures access to obstetrical and gynecological care without precertification. The plan complies with the Mental Health Parity and Addiction Equity Act, ensuring parity in quantitative and non-quantitative treatment limitations for mental health and substance use disorder benefits. Coverage for children under a Qualified Medical Support Order is permitted. The plan provides timely access to care, with specific timeframes for urgent and non-urgent appointments for medical and mental health services. Telehealth visits are covered similarly to in-person visits, and out-of-pocket costs count toward deductibles and out-of-pocket limits. The plan includes provisions for confidential communication of medical information and non-discrimination. Certain hospitals and providers may not offer services such as family planning, contraception, sterilization, infertility treatments, or abortion. The plan outlines benefit details including deductibles, coinsurance, and out-of-pocket limits for in-network and out-of-network services. Specific benefits are detailed for services such as acupuncture, ambulance services, bariatric surgery, diabetes care, mental health, and prescription drugs. The plan also covers travel expenses for designated bariatric and gender affirming surgeries. The Claims Administrator provides administrative services only and does not assume financial risk for claims. The plan is governed by ERISA, and members have rights to examine plan documents and file claims. The plan includes continuity of care provisions for new members and those whose providers leave the network.

Synopsys (SNPS) has reported strong Q3 results, with revenue up 42% year over year and non-GAAP EPS at $3.91, above guidance. Management lifted full-year revenue guidance to $9.69 billion to $9.74 billion and raised non-GAAP operating margin guidance to 41.5%. The company expects EDA growth to accelerate to double digits in Q4 and for the full year, driven by healthy underlying demand and a solid pipeline. Synopsys also showcased agentic AI capabilities and launched Multiphysics Fusion, its first integrated Synopsys-Ansys solution, with early adopters reporting significant design closure and runtime improvements.

New chips and architectures Hot Chips brought a wave of new processor and accelerator details this week, alongside Apple’s latest M-series silicon: IBM and Arm unveiled a 2nm dual-architecture processor for future IBM Z and LinuxONE systems, with cores designed to execute both IBM and Arm instructions and support Arm-native Linux alongside existing IBM workloads.